What was recalled
This page synthesizes the strain-specific evidence framework around Lactobacillus acidophilus supplementation in commercial pet food. The species was first described in 1900 as Bacillus acidophilus by Moro and reclassified into the Lactobacillus genus in 1923. The 2020 taxonomic reclassification splitting the historical Lactobacillus genus into 25 new genera retained acidophilus as part of the Lactobacillaceae family, though many regulatory documents (AAFCO, FDA, EFSA) continue to use the historical Lactobacillus acidophilus naming. The species is a natural inhabitant of human and companion-animal gastrointestinal tracts, oral cavities, and vaginal microbiota; produces lactic acid through homofermentative metabolism of glucose; tolerates moderate gastric acidity (survives passage through stomach pH 3-4 in significant numbers); and adheres modestly to intestinal epithelial cells through surface-layer (S-layer) proteins.
The commercial strain landscape includes dozens of distinct strains commercialized through different proprietary developments: (i) LA-5 (Chr. Hansen / Novonesis, paired with BB-12 in many human dairy and pet food applications, deposited at DSM under accession DSM 13241); (ii) NCFM (DuPont / IFF, originally isolated 1975 at North Carolina State University by Klaenhammer, one of the most-studied strains globally with 100+ publications); (iii) DDS-1 (UAS Laboratories, used in many dietary supplements); (iv) La-14 (DuPont / IFF, used in dairy and supplements); (v) La1 / La5 (various commercial sources). Each strain carries its own genomic sequence, surface protein profile, bacteriocin production capacity, and adhesion characteristics. Genomic-level differences between commercial L. acidophilus strains are sufficient that some researchers argue the species name is too broad and should be subdivided.
The companion-animal evidence base for L. acidophilus is dominated by multi-strain trial designs that include L. acidophilus as one component. Published trials in dogs and cats include: (i) Marshall-Jones 2006 (J Vet Intern Med, multi-strain formulation with primarily Enterococcus faecium SF68, L. acidophilus as adjunct, in healthy adult dogs); (ii) Bybee 2011 (J Vet Intern Med, multi-strain in shelter dogs, primary endpoint diarrhea incidence); (iii) Schmitz 2014 (J Vet Intern Med, multi-strain in dogs with chronic enteropathy); (iv) Lappin 2009 (J Feline Med Surg, multi-strain in cats). Single-strain L. acidophilus trials in companion animals are substantially less common, and most do not specify strain identity at the publication level (referring only to "L. acidophilus" without DSM, ATCC, or proprietary identifier).
Why it was recalled
The structural concerns have three layers. Layer one — strain identity is rarely disclosed on pet food labels: AAFCO labeling rules permit ingredient listing at the species level (Lactobacillus acidophilus) without strain-level identification (DSM number, ATCC number, or proprietary strain code). The framework simplifies labeling but obscures the evidence-quality framework at the consumer-facing tier. A pet food containing well-studied NCFM at therapeutic CFU and a pet food containing a commodity-grade strain at minimum-detection CFU will appear identical on the label.
Layer two — evidence does not transfer across strains: probiotic effects are highly strain-specific. NCFM evidence for stool quality in adult humans does not apply to LA-5; DDS-1 evidence for vaginal microbiota does not apply to La-14; LA-5 evidence for human dairy fermentation tolerance does not apply to most other strains. The non-transferable nature of strain-specific evidence is well-established in microbiology literature but poorly communicated at consumer-facing pet food marketing tiers. Consumer-facing marketing typically lumps "L. acidophilus benefits" across all strains, which is not scientifically supported.
Layer three — commodity-grade strain sourcing is common in cost-sensitive pet food: well-studied strains like NCFM and LA-5 typically cost 3-10x more per CFU than commodity-grade L. acidophilus strains. Commercial pet food formulators with cost pressure may select commodity-grade strains to achieve a probiotic-fortification claim without the higher cost of evidence-tier strains. The substitution is invisible to consumers reading the label (which lists only "L. acidophilus" without strain identity) and produces a marketing-versus-evidence gap where the label claim is technically accurate but the underlying evidence base is substantially weaker than the consumer would infer from L. acidophilus literature generally.
Health risks for your pet
L. acidophilus safety profile is generally favorable across all commercial strains. EFSA QPS status applies to the species level; FDA GRAS notices apply to specific strains. No documented serious adverse events at commercial pet food dosing (10^6 to 10^9 CFU/g of food). Theoretical safety considerations include: (i) bacteremia in severely immunocompromised animals (rare; documented case reports in human medicine are almost entirely with Lactobacillus rhamnosus GG, very rare with L. acidophilus); (ii) D-lactic acidosis in animals with short bowel syndrome (some L. acidophilus strains produce D-lactate alongside L-lactate; rare clinical relevance at commercial dosing); (iii) transient bloating, flatulence, or stool consistency change during initial supplementation (common, resolves 1-2 weeks); (iv) interaction with concurrent antibiotic therapy (probiotic CFU drops during antibiotic courses; co-administration timing typically separated by 2-4 hours from antibiotic dose).
The health-outcome concerns for pet owners are primarily evidence-quality rather than safety. A pet owner selecting L. acidophilus-containing pet food for a specific health goal (chronic enteropathy management, antibiotic-associated diarrhea prevention, immune support, oral microbiota support) cannot easily distinguish products with well-studied strains from products with commodity-grade strains. The evidence framework gap is invisible at the label tier and rarely surfaces in brand marketing.
What to do if you bought affected product
Pet owners can navigate the L. acidophilus framework meaningfully through several practical approaches: (1) contact brand customer service to confirm strain identity — established brands using well-studied strains (NCFM, LA-5, DDS-1) will typically confirm strain identity with Certificate of Analysis or supplier documentation; if the brand cannot or will not confirm strain identity, the product likely uses a commodity-grade strain with thinner evidence; (2) look for products specifying strain-level identity on the label or in product literature — some premium pet food brands voluntarily disclose strain-level sourcing as a transparency signal; (3) recognize that multi-strain formulations are common in pet food — products listing 5-10 probiotic strains often include L. acidophilus alongside Enterococcus faecium, Bifidobacterium animalis, L. plantarum, L. rhamnosus, and others; multi-strain formulations may produce broader effects than single-strain but with less strain-specific evidence per component; (4) for specific therapeutic goals, consider veterinary-tier supplements rather than baseline probiotic-fortified kibble — FortiFlora (Enterococcus faecium SF68 NCIMB 10415), Proviable (multi-strain), Visbiome Vet (8-strain VSL#3-derived formulation), and similar products carry stronger evidence and higher CFU dosing than baseline probiotic-fortified pet food; (5) request CFU-at-end-of-shelf-life rather than CFU-at-manufacture — lactobacilli lose viability across shelf life, particularly under typical pet food storage conditions (room temperature, humidity exposure post-opening); (6) treat L. acidophilus inclusion as a baseline gut-health support rather than a therapeutic intervention — the species is safe and likely useful at the population level, but specific health goals benefit from strain-specific evidence-based product selection; (7) watch for marketing language that conflates species and strain evidence — "clinically proven L. acidophilus" without strain identification typically signals lower evidence quality than products specifying strain identity, dose, and trial evidence base.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate probiotic strain identity in scoring per our published methodology, since strain identity is rarely disclosed on pet food labels. Future rubric extension under consideration: brands publishing strain-level sourcing (DSM, ATCC, or proprietary accession), CFU-at-end-of-shelf-life guarantees, and trial evidence citations would receive favorable scoring weight as transparency signals. Related framework coverage is across our L. acidophilus explainer, L. plantarum explainer, L. rhamnosus explainer, and probiotic strain viability controversy. For now, our recommendation: treat L. acidophilus inclusion as evidence-supported at the species level with safety-cleared use in companion animals, but expect strain-specific evidence quality to vary substantially across commercial sourcing and rarely surface at the consumer-facing label tier.